FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...

Can the medicine for treatment of rare disorder spinal muscular atrophy (SMA) be made available at lower price in India if it ...

The Supreme Court of India seeks responses from the Centre and Roche on making the spinal muscular atrophy treatment drug ...

Intrathecal treatment with a vector-based gene therapy was associated with a greater improvement in motor function at 52 ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

The FDA has accepted for Priority Review the BLA for apitegromab for the improvement of motor function in patients with spinal muscular atrophy.

A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...

Malayalam director and writer Dr Siju Vijayan talks about his childhood fascination with cinema and the challenges of ...

In what could be promising news for patients battling spinal muscular atrophy (SMA), the Delhi High Court has refused to ...

for apitegromab for the improvement of motor function in patients with spinal muscular atrophy (SMA). Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and ...